Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Decides Year-End Cash Dividend of KRW 750 per Common Share, Totaling KRW 164B (Tax-Free Funding)

Posted on December 11, 2025July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides Year-End Cash Dividend of KRW 750 per Common Share, Totaling KRW 164B (Tax-Free Funding)

Source: Financial Supervisory Service DART System / 2025-12-11

Disclosure Type: Decision on Cash/Valuable Property Dividend

💡 3-Second Summary

Celltrion has decided to pay a year-end cash dividend of KRW 750 per common share, totaling approximately KRW 164B (USD 111.5M). The dividend will be sourced from tax-free capital surplus reductions, meaning shareholders will not be subject to income tax on these payouts.

📊 1. [Summary of Core Disclosure Content and Major Figures]

Celltrion’s Board of Directors has resolved to distribute a year-end cash dividend. The details of the dividend and its criteria are outlined below:

  • Dividend Type and Classification: Year-end dividend / Cash dividend (No differential dividend applied)
  • Dividend per Share: KRW 750 for common shares (No dividend for preferred shares)
  • Dividend Yield to Market Price: 0.4% for common shares (Calculated based on the arithmetic average of the closing prices on the market for one week prior to the business day preceding the Board’s decision)
  • Total Dividend Amount: KRW 163,959,843,000 (Approx. KRW 164B)
  • Shares Eligible for Dividend: 218,613,124 shares (Calculated by excluding 12,347,845 treasury shares from the total outstanding shares of 230,960,969 as of Dec 11, 2025)
  • Key Dates:
    • Dividend Record Date: Dec 31, 2025
    • Board Resolution Date: Dec 11, 2025 (8 outside directors attended, 0 absent)
    • General Shareholders’ Meeting and Payment Schedule: The scheduled date for the shareholder meeting is unconfirmed and will be disclosed later. Dividend payments are planned to be distributed within one month after the resolution of the general meeting.
  • Funding Source and Taxation: Sourced from a portion of the capital surplus reduced through a resolution at the 34th annual general meeting on March 25, 2025. This payout is classified as non-taxable income under relevant laws (Article 26-3 of the Enforcement Decree of the Income Tax Act, Article 18 of the Corporate Tax Act).

📈 2. [Expert View: What This Disclosure Means for Investors]

This dividend announcement involves tax benefits from structural planning and potential shifts in share counts, requiring careful attention to detail from investors.

  • Tax-Free Dividend Effect via Capital Surplus Reduction: Over 99% of this dividend is funded by the reduction of capital surplus. Under local tax regulations, distributions made from this specific capital resource are not considered taxable income, meaning shareholders can receive their dividends in full without withholding tax deductions.
  • Potential Fluctuation in Total Payout Due to Treasury Shares: The total dividend amount was calculated excluding treasury shares held as of the Board meeting date. The number of treasury shares may fluctuate depending on the receipt of appraisal rights from shareholders, which could lead to a revision of the total dividend amount once the shareholder registry is verified on the record date (Dec 31, 2025).
  • Uncertainty Pending Shareholders’ Meeting Approval: The dividend per share of KRW 750 is an agenda item to be submitted to the upcoming 35th annual general meeting of shareholders. The final terms remain subject to change depending on the outcome of the general meeting and the external auditor’s final review.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s board has proposed a year-end cash dividend of KRW 750 per common share. While the market dividend yield stands at a modest 0.4%, the structure of the funding is highly advantageous. Sourced from a reduction in capital surplus rather than retained earnings, this payout is legally tax-exempt, meaning investors can pocket the entire gross amount without any tax drag.

However, shareholders must keep in mind that this proposal must secure final approval at the upcoming annual general meeting before the payment schedule and amounts are officially locked. Furthermore, because ongoing corporate events such as stock purchase requests could change the number of treasury shares before the record date of December 31, 2025, the final aggregate payout remains subject to minor adjustments. Keeping a close eye on subsequent filings regarding the official meeting date and registry adjustments is highly recommended.

📢 Disclaimer & Sources

Source: This content was structured and newly written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Subsidiary Celltrion USA Confirms Dec 31, 2025 as Acquisition Date for 100% Stake in Imclone Systems LLC (KRW 460B)
Next Post: [Disclosure] Celltrion (068270) Sets December 31, 2025 as Record Date to Determine Shareholders Eligible for Year-End Dividend

Related Posts

[Disclosure] SK Hynix(000660) Finalizes Terms for US Nasdaq-Listed ADR Issuance; Secures KRW 40 Trillion for Large-Scale Facility Investments Disclosures
[Disclosure] Samsung Biologics (207940) Pre-Announces Financial Results Disclosure Date… Slated for January 21 Disclosures
[Disclosure] Alteogen (196170) to Hold AGM on March 31; Agenda Includes Re-appointment of CEO Park Soon-jae and Appointment of VP Choi Sang-rak as Inside Director Disclosures
[Disclosure] SK Hynix (000660) Disposes of Treasury Shares for Stock Option Exercise… Total of 9,007 Shares Semiconductors
[Disclosure] Celltrion (068270) Submits Application for Domestic Marketing Authorization of ‘CT-P6 SC’ (Herzuma Subcutaneous Formulation) Disclosures
[Disclosure] Celltrion (068270) Submits Application for Domestic Marketing Authorization of ‘CT-P55’ (Cosentyx Biosimilar) Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme